LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Strona główna・Stock List・ADMA Biologics Inc

ADMA Biologics Inc

Closed

Sector Healthcare

13.15 0.54

Buy Sell

Overview

Share price change

24h

Current

Min

12.92

Max

13.33

Key metrics
By Trading Economics
Income	35M 18M
Sales	8M 82M
EPS	0.08
Profit margin	21.748
Employees	624
EBITDA	7.9M 24M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	-6.91 downside

Dividends
By Dow Jones
Next Earnings	7 sie 2024

Market Stats
By TradingEconomics
Market Cap	450M 3.1B
Previous open	12.61
Previous close	13.15

News Sentiment

By Acuity

31%

69%

66 / 369 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

13.05 / 13.73 Support & Resistance

ADMA Biologics Inc Chart

Related News

26 lip 2024, 22:06 UTC

Major Market Movers

vTv Therapeutics Shares Tumble After FDA Pauses Diabetes-Treatment Study

26 lip 2024, 19:26 UTC

Earnings

Trending: 3M Shares Surge On Earnings

26 lip 2024, 17:40 UTC

Earnings

Merck KGaA FY24 Outlook Improves After Strong Second Quarter

26 lip 2024, 17:21 UTC

Major Market Movers

Aon Shares Rise Following Better-Than-Expected 2Q Results

26 lip 2024, 22:40 UTC

Acquisitions, Mergers, Takeovers

Burger King Parent Company and More Stocks See Action From Activist Investors -- Barrons.com

26 lip 2024, 21:27 UTC

Market Talk

Consumers Are Skipping Starbucks' Half-Priced Drinks -- Market Talk

26 lip 2024, 20:54 UTC

Earnings

3M Stock Had Its Best Day Ever. The New CEO Started With a Bang. -- Barrons.com

26 lip 2024, 20:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

26 lip 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 lip 2024, 20:50 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

26 lip 2024, 20:50 UTC

Peer Comparison

Price change

ADMA Biologics Inc Forecast

Price Target

By TipRanks

-6.91% downside

12 Months Forecast

Average 12.25 USD -6.91%

High 15 USD

Low 10 USD

Based on 4 Wall Street analysts offering 12 month price targets forADMA Biologics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to ADMA Biologics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

13.05 / 13.73Support & Resistance

Recent bearish events outweigh bullish events.

There are no events.

All events are bullish.

Sentiment

By Acuity

66 / 369 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ADMA Biologics Inc

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.